BTRP011L

N/A

Report date: 2024/11/21 10:21:20
First In Class

Base Information

Drug NameBTRP011L
Drug Alias NameBTRP011LBTRP-011L
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsUpdating
Therapy Area/IndicationsGastrointestinal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGuangzhou Baiji Biopharmaceutical Co LtdBiosyngen Pte Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Baiji Biopharmaceutical Co LtdBiosyngen Pte Ltd
Inactive CompaniesN/A
Active IndicationsGastrointestinal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A